Investigator
Atul Varadhachary
FANNIN PARTNERS, LLC · funded by NEI, NCI
- Companies
- 1
- Grants
- 2
- Non-dilutive funding
- $1.3M
- First award
- Apr 1, 2022
Resolved onto their grants.
Federal awards on file.
Summed across those awards.
Latest Sep 1, 2025.
Companies from this work
Pre-ticker companies the crosswalk resolved onto a grant filed under this investigator. Momentum shows for the therapeutic areas your seat covers; open a dossier for the full crosswalk.
- FANNIN PARTNERS, LLC39momentum
OncologyGrant-only
Grant record
Federal awards filed under this investigator name, newest first. Each links to the public record where the awarding agency publishes one.
- R43
Developing Scg3 Raptamers as a novel targeted therapy for wet AMD
$300kSep 1, 2025NEIFANNIN PARTNERS, LLCNIH RePORTER · 11182159 (opens the source filing in a new tab)
- R44
Early clinical development of a novel IL-7R antibody for treating children with relapsed T-cell leukemia
$1000kApr 1, 2022NCIFANNIN PARTNERS, LLCNIH RePORTER · 10598447 (opens the source filing in a new tab)
This page aggregates public U.S. federal grant records filed under one investigator name and the companies Biodatica has resolved onto them. Names are shown as the awarding agency filed them; grant awards are non-dilutive federal funding, not equity or valuation. Distinct people who file under the same name would appear together here. It is informational only and not investment advice. Methodology · Data sources